{"id":289476,"date":"2023-04-21T18:07:33","date_gmt":"2023-04-21T23:07:33","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=289476"},"modified":"2023-04-21T18:18:50","modified_gmt":"2023-04-21T23:18:50","slug":"supreme-court-abortion-pill-market","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/supreme-court-abortion-pill-market\/","title":{"rendered":"Supreme Court allows the abortion pill to remain on the market — for now"},"content":{"rendered":"
<\/div>

The Supreme Court issued an order<\/a> allowing mifepristone to remain on the market, while legal proceedings regarding its FDA approval continue. The ruling was released in response to last week’s U.S. Court of Appeals for the Fifth Circuit’s decision regarding the distribution of mifepristone, the first drug of the abortion pill regimen. On Friday, the Court had temporarily ruled<\/a> to allow the abortion pill to be dispensed by mail until it issued its decision. Five days later, the Supreme Court extended by 48 hours the stay, allowing the pill to be dispensed by mail.<\/p>\n

On April 12, the Fifth Circuit issued a partial stay on U.S. District Judge\u00a0Matthew J. Kacsmaryk’s April 7 decision to suspend the FDA approval of the abortion pill. After the Department of Justice (DOJ) appealed Kacsmaryk’s decision, the Fifth Circuit ruled that the abortion pill could continue to be distributed, but reinstated safety requirements dating back prior to 2016. Those rules required that the abortion pill be dispensed in person<\/em> by a certified prescriber,\u00a0that it could only be taken up to seven weeks, of pregnancy, and that all<\/em> adverse events related to the abortion pill would once again need to be reported \u2014\u00a0not just women’s deaths.<\/p>\n